Form 4: Syros Pharmaceuticals Director Richard A. Young Acquires Shares and Options

Director Richard A. Young of Syros Pharmaceuticals acquired 4,000 shares of common stock and options to purchase 6,000 shares on June 5, 2024.

Summary

• On June 5, 2024, Richard A. Young, a director of Syros Pharmaceuticals, acquired 4,000 shares of common stock at $0.00 per share.
• On the same date, Young also acquired options to purchase 6,000 shares of common stock at an exercise price of $5.30.
• Following these transactions, Young directly owns 42,837 shares of common stock and options to purchase 6,000 shares.
• The options vest over a one-year period, with 50% vesting after six months and the remainder vesting in equal monthly installments.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a standard transaction by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider activity.

Positives

• The director's acquisition of shares and options could be interpreted as a positive signal about the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive sign, potentially increasing confidence in the company.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Richard A. Young, Stock Options, Share Acquisition, Beneficial Ownership, Form 4, SYRS